Flumequine (FL), a quinolone-antibiotic used for veterinary treatment of infections, was found to elicit hepatocellular tumors in a conventional 18-month carcinogenicity study in mice, and hepatocellular necrosisregeneration cycle was considered to be a possible underlying mechanism. In order to clarify whether FL has any modifying effects on development of hepatocellular proliferation, groups of heterozygous p53 deficient CBA mice [p53(+/-) mice], sensitive to genotoxic carcinogen, of both sexes and their wild-type littermates [p53(+/+) mice] were fed diet containing 4,000 or 0 ppm FL for 26 weeks after an intraperitoneal injection of 5 or 0 mg/kg body weight of dimethylnitrosamine (DMN). Higher incidences of hepatocellular foci were observed in animals receiving FL, with or without DMN-initiation, than in the corresponding control groups in both p53(+/-) and p53(+/+) mice. Incidences and multiplicities of foci were generally similar in p53(+/-) and p53(+/+) mice, but, in the DMN+FL group, multiplicity of foci and their PCNA labeling indices were greater in p53(+/-) mice. There were also small numbers of hepatocellular adenomas and carcinomas in the DMN+FL group of p53(+/-) mice, hepatocellular adenoma in the FL alone group of p53(+/-) mice, and hepatocellular adenomas in the DMN+FL group of p53(+/+) mice. Induction of hepatocellular tumors in these mice within a relatively short period strongly suggests that mechanisms such as direct or indirect damage to DNA might be responsible for the hepatocarcinogenesis of FL. (J Toxicol Pathol 2001; 14: 135-143) 
Introduction
Flumequine is a fluoroquinolone-antimicrobial agent which is predominantly active against Gram-negative bacterias 1 . It has been used by veterinarians for the treatment of urinary tract infections, and the parent drug and/or its metabolites are suspected to persist in edible tissues. It has been reported that flumequine induced hepatocellular tumors in a 18-month carcinogenicity study in mice 2 . In 1997, safety assessment of the drug was performed by the Food and Agriculture Organization (FAO)/World Health Organization (WHO) Joint Expert Committee on Food Additives (JECFA) 3 . The following results of toxicological studies of flumequine were taken into account: i) Hepatocellular tumors were associated with hepatic damage such as hepatocellular degeneration and necrosis; ii) hepatic drug-metabolizing enzyme induction or peroxisomal proliferation were not observed; and iii) there was no evidence of genotoxicity of flumequine in in vitro bacterial or mammalian cells gene mutation assays and in vivo chromosomal aberration test in bone-marrow cells of rats. The JECFA thus considered that the induction of hepatocellular necrosis-regeneration cycles due to hepatotoxicity was the relevant mechanism for the hepatocarcinogenicity of flumequine, and an acceptable daily intake (ADI) was calculated based on the no-observedeffect-level (NOEL) of hepatotoxicity. However, the bacterial gene mutation assay is not always reliable for detection of genotoxicity of the chemicals with antimicrobial activity such as flumequine, because the concentrations examined are usually limited to low levels. Moreover, there is no information concerning the damage to the genes in hepatocytes that proved to be target cells in the long-term carcinogenicity study. Furthermore, Yoshida et al. 4 reported that flumequine not only enhanced a development of altered foci and adenomas of the hepatocytes in CD-1 mice by dietary administration at 4,000 ppm for 30 weeks after an initiation of diethylnitrosamine, but also induced small numbers of hepatocellular foci at the same dose without any initiation. Moreover, 8-hydroxy-2'-deoxyguanosine (8OH-dG), a product of oxidative stress on DNA 5 , was found in hepatocytes of these treated mice. The results suggest that direct or indirect genetic damage as well as liver tumor promoting effects may participate in the hepatocellular carcinogenicity of flumequine.
It has been reported that heterozygous p53 deficient mice, p53(+/-) mice, in which the lateral allele of the p53 gene is inactivated, provide a useful model to detect the carcinogenic potential of genotoxic carcinogens within short-term treatment period of less than 6 months [6] [7] [8] [9] [10] . They were therefore employed in the present study in order to clarify whether flumequine has any promoting or t u m o r i g e n i c a c t i v i t y f o r t h e l i v e r u n d e r dimethylnitrosamine-initiated or non-initiated condition.
Materials and methods

Test substance
Flumequine p53(FL) was obtained as a white fine crystalline powder from Kyowa Hakko Kogyo (Tokyo, Japan) and admixed into basal diet (CRF-1 ® , Oriental Yeast Co., Tokyo, Japan) at 4,000 ppm. The diet was freshly prepared every week. Dimethylnitrosamine (DMN) obtained from Nacarai Tesque Inc. (Kyoto, Japan) was dissolved in saline and passed through a membrane filter with 0.22 µm pore size (MILLEX-GV, Japan Millipore Ltd., Tokyo Japan) just before usage.
Experimental animals
The mice used in the present study were heterozygous p53 deficient CBA mice [p53(+/-) mice] in which exon 2 of the lateral p53 allele was inactivated, being F1 offspring of heterozygous p53 deficient C57BL/6J male mice backcrossed with CBA female mice 11 . Forty-one male and 27 female p53(+/-) mice, and 42 male and 32 female wild-type littermates [p53(+/+) mice] were purchased from Oriental Yeast Co. and used after an acclimatization period of 1-week. The animals used were 9-10 weeks of age in males and 12-13 weeks of age in females, at the start of the study. They were housed at a maximum of 5 per cage in plastic cages with soft chip bedding in a room that was controlled for light-dark cycle (12-12 hours, lights on 7:00-19:00), ventilation (air-exchange rate of 18 times per hour), temperature (21-25°C) and relative humidity (50-60%) during the study. The cages and the chip bedding were exchanged for new ones twice a week. Each animal had free access to powdered diet (CRF-1 ® , Oriental Yeast Co.) and tap water.
Experimental design
Both p53(+/-) and p53(+/+) mice were randomly allocated into four experimental groups based on their body weights. Two groups of p53(+/-) mice of both sexes received a single intraperitoneal injection of DMN at 5 mg/ kg body weight. One of their groups was fed the diet containing 4,000 ppm FL for 26 weeks, commencing 1-week after DMN injection, and the other group, serving as a control, was fed basal diet for the same period. The remaining two groups of both sexes were maintained with the FL-admixed diet or basal diet for 26 weeks without DMN initiation. The four groups of p53(+/+) mice of both sexes were also subjected to the same treatment as their p53(+/-) counterparts. During the study period, the animals were observed once a day for their general condition, and weighed once weekly.
Histopathological examination
At the end of treatment period, surviving animals were sacrificed under ether anesthesia and necropsied. After measuring the liver weights, a wide variety of organs and tissues, including the liver, were fixed in 10% neutral buffered formalin for routine histopathological processing. Liver tissue specimens were trimmed from the designated left, median and caudate lobes. Then, paraffin-embedded sections with 4-5 µm thick were stained with hematoxylin and eosin. Histopathological examination was performed on these sections of each animal. In addition, tissue sections were immunohistochemically stained for proliferating cell nuclear antigen (PCNA) using an anti-PCNA mouse monoclonal antibody (DAKO, Glostrup, Denmark) at dilutions of 1:100 and avidin-biotin peroxidase complex kits (Burlingame, CA, USA) with a chromogen of 3, 3'-diaminobenzidine followed by counterstaining with hematoxylin. Moreover, in order to detect apoptotic cells, in situ detection kit for terminal deoxyribonucleotidyl transferase-mediated deoxyuridine triphosphate-dioxygenin nick end labeling (TUNEL) was employed according to the manufacturer's instructions. Labeling of cells forming each proliferative lesion was examined for up to 1000 cells from different areas and indices for PCNA or TUNEL positivity were calculated as a percentage.
Statistical analysis
The two-tailed Student's t-test was used to test for significant differences between groups in the PCNA and TUNEL labeling indices as well as body and liver weights. Incidences of hepatic proliferative lesions observed were analyzed with Fisher's exact test. Significance was inferred at either 5% or 1% level.
Results
Three male and two female p53(+/-) mice receiving FL after DMN-initiation (DMN+FL), 3 male p53(+/-) mice receiving FL without DMN-initiation (FL alone) and one male p53(+/+) mouse each in the DMN+FL and FL groups died due to the treatment (Table 1) . A few p53(+/-) mice in other groups also died due to lymphomas or lung adenocarcinomas. Male p53(+/-) and p53(+/+) mice in the DMN+FL and FL alone groups showed depression of body weight gain, when compared to the corresponding basal diet groups with DMN-initiation (DMN alone) or without initiation (Basal diet) ( Figs. 1 and 2 ). In females, suppression of body weight gain in the DMN+FL p53(+/-) mice became evident after week-20 in comparison with the DMN alone group, but their growth curve was similar to that in the basal diet group (Fig. 1) .
Terminal body weights in the DMN+FL group of p53(+/-) and p53(+/+) females and the FL-treated groups of p53(+/+) males were significantly lower than those in the control groups. Relative liver weights were increased in the DMN+FL and FL alone groups of male p53(+/+) and female p53(+/-) and p53(+/+) mice compared to the DMN alone and basal diet groups, respectively, associated with an increase in absolute liver weights in the FL alone group of female p53(+/-) mice and the DMN+FL group of female p53(+/+) mice.
In histopathological examination, hepatocellular altered foci were observed in almost all surviving males and females (93 to 100% incidence) receiving FL with or without DMNinitiation, their incidences being higher than those in the DMN alone (10 to 67%) and basal diet (0 to 17%) groups, respectively ( Table 2) . Phenotypes of the foci were predominantly clear cell type, and eosinophilic cell type was sometimes mixed in several clear cell foci (Fig. 3) . No difference in phenotypes of the foci was seen among groups (data not shown). In addition, the administration of FL after DMN initiation was associated with small numbers of hepatocellular adenomas and/or carcinomas in males and females of p53(+/-) mice and p53(+/+) males. FL treatment without DMN initiation also induced a hepatocellular adenoma in one male p53(+/-) mouse. The numbers of the altered foci per animal in the DMN+FL and FL alone groups were increased with statistical significance as compared to respective control groups in both p53(+/-) and p53(+/+) mice (Table 2) , without any difference noted between the DMN+FL and the FL alone groups. Foci in the DMN+FL and FL alone groups were more frequent in males than in females. Their multiplicity in female p53(+/-) mice of the DMN+FL group was greater than in their p53(+/+) counterparts.
PCNA labeling indices of hepatocellular foci in the DMN+FL and FL alone groups were also increased in p53(+/-) mice compared to p53(+/+) mice, with statistical significance in the DMN+FL group of both sexes (Fig. 4) . PCNA labeling indices in nonproliferative areas of the liver did not differ between p53(+/-) and p53(+/+) mice, but were higher in the DMN+FL and FL alone groups than in the corresponding controls (Table 3) . TUNEL labeling indices of foci in female p53(+/-) mice in the DMN+ FL group showed a marked increase as compared to p53(+/+) and a similar trend was also noted for females of the FL alone group (Fig. 5) . Other than the proliferative lesions, single cell necrosis of hepatocytes and anisonucleosis were observed in males and females of the DMN+FL and FL alone groups of p53(+/-) and p53(+/+) mice (Table 3) .
Discussion
With respect to modification of proliferative hepatocyte lesions in mice of CBA-origin in the present study, administration of FL following DMN initiation increased the incidences as well as multiplicities of hepatocellular altered foci in both p53(+/-) and p53(+/+) mice, and induced hepatocellular adenomas and carcinomas in p53(+/-) mice Since no such proliferative lesions were not observed in the animals fed basal diet in the present study in line with our previous 26-week study 10 , the induction can be considered due to the FLtreatment.
Yoshida et al. also reported proliferative hepatocyte lesions in CD-1 (ICR) mice after administration of FL, with or without prior DEN-initiation, for a maximum of 30 weeks, but the lesions induced by FL alone treatment were infrequent and much lower than those induced by FLtreatment after DEN-initiation. In contrast, in our study, proliferative lesions were numerous, and enhanced development of proliferative lesions was not remarkable in the DMN+FL group in comparison with those in the FL alone group. The carcinogen used for the initiation treatment and the mice used were different in these two studies, but the influence of incomplete deficiency of p53 gene may be limited, because the susceptibility of p53(+/-) mice to FLinduced hepatocellular proliferation was generally similar to that in p53(+/+) mice. Higher responses observed only in p53(+/-) mice included the multiplicity, PCNA expression and TUNEL positivity of hepatocellular foci in females of the DMN+FL group and PCNA expression in males of the DMN+FL group. P53 is recognized as one of proapoptotic genes 12, 13 and can repress a prosurviving factor 14 . However, involvement of p53 gene in PCNA expression in hepatocytes is controversial. In the study by Yin et al., basal PCNA labeling index and thymidine uptake in hepatocytes were high in p53(+/-) mice compared to their wild counterparts 15 , while Delker et al. demonstrated that loss of p53 gene was not associated with the increased number of PCNA positive hepatocytes 16 . Moreover, spontaneous and chemicallyinduced apoptosis was not controlled by status of p53 gene in these studies 15,16. Since our data demonstrated higher expression of PCNA labeling index only in the DMN+FL group but not in other groups including the FL alone group, the involvement of p53 gene in PCNA expression, if any, is limited. Our results suggest a higher susceptibility of CBA mice to FL-induced hepatic tumorigenesis. Moreover, multiplicities of hepatocellular foci were higher in males than in females in both the DMN+FL and FL alone groups of p53(+/-) and p53(+/+) CBA mice, suggesting high susceptibility of males.
Regarding mechanisms of induction of hepatic proliferative lesions by FL, a number of possibilities can be considered. Firstly, the percentage of spontaneous gene mutations may be increased due to recurring hepatocellulardeath and regeneration. Microscopic examination in our study revealed frequent single cell necroses and anisonucleosis of hepatocytes. The higher PCNA labeling indices in background parenchyma in the DMN+FL and FL alone groups as compared to the corresponding control groups provide clear evidence of response to hepatic damage. This might account for a lack of clear difference of susceptibility to FL-induced hepatocarcinogenesis in p53(+/-) and p53(+/+) mice. This interpretation is consistent with the conclusion of the 48th JECFA. In this respect, FL might be considered a non-genotoxic hepatocarcinogen so that a threshold dosage can be set based on the NOEL for the hepatotoxicity. However, there remained unsolved points concerning the occurrence of spontaneous gene mutation by FL treatment. The administration of FL without prior initiation induced hepatocellular proliferative lesions within a short latent period in the present study. We can not demonstrate the enhanced carcinogenic susceptibility of p53(+/-) mice in contrast to the previous data for distinguishing genotoxic carcinogens from noncarcinogens 6 -1 0 . A lack of enhancement of hepatocellular proliferation has been also proved in the TSG-p53(+/-) ® mouse, which is another type of p53-deficient mouse derived from C57BL/6 background. TSG-p53(+/-) mice did not show higher susceptibility to DMN-induced hepatocellular proliferation as compared with their wild type mice, while they showed higher susceptibility in terms of 5-bromo-2'-deoxyuridine labeling index to proliferation of epithelial cells of the urinary bladder induced b y N -b u t y l -N -( 4 -h y d r o x y b u t y l ) -n i t r o s a m i n e 1 7 . Phenobarbital, a potent hepatocellular tumor promoter in rodents 18 , and pentachlorophenol, a hepatocarcinogen with hepatotoxic activity in mice 19 , failed to induce hepatocellular tumors in TSG-p53(+/-) mice 20, 21 . Therefore, the role of p53 gene in hepatocellular carcinogenesis and the advantages of p53(+/-) mice for detecting hepatocellular carcinogens are issues of future investigations. Regarding the genotoxicity of FL, the 48th JECFA concluded no apparent evidence of genotoxicity of FL, assays using hepatocytes, target cells of the FL-induced tumorigenesis, for in vivo UDS test or for DNA damage or DNA adduct were not performed in FL. Therefore, the possibility that FL exerts a direct genotoxic effect on hepatocytes can not be ruled out. However, since a relatively higher dose of FL was selected in the present study according to the results of previous study, FL-induced hepatotoxic changes make the evaluati on of the hepatocarcinogenesis difficult. Further experiments addressing on genetic alteration will be necessary to elucidate the precise mechanisms of hepatocarcinogenicity of FL. A third possible mechanism is that indirect genotoxicity may occur. Yoshida et al. 4 showed that 8OH-dG was present in periportal hepatocytes and duct epithelial cells. They thus considered that the oxidative stress to DNA might be an important factor for the induction of proliferative lesions. Although the mechanism for the induction of 8-OHdG after administration of FL remains uncertain, the indirect damage of DNA might participate the tumorigenesis of FL.
In conclusion, in contrast to most short-term carcinogenicity studies of non-genotoxic carcinogens or promoters in p53(+/-) mice 20, 21 , FL induced proliferative lesions of hepatocytes in p53(+/-) as well as p53(+/+) CBA mice after 26-week treatment independent of prior DMN initiation. Therefore, it is strongly suggested that unverified mechanisms such as direct/indirect damage to hepatocellular DNA are responsible for the tumorigenesis of FL in addition to proliferation-dependent tumor promoting effects. 
